Currently available and potential future treatment options for IgA nephropathy

Bibliography

• Donadio JV, Grande JP. IgA Nephropathy. N Engl J Med 2002;347(10):738-48
   PubMed Web of Science ®Google Scholar
• Berthoux FC, Mohey H, Afiani A. Natural history of primary IgA nephropathy. Semin Nephrol 2008;28:4-9
   PubMed Web of Science ®Google Scholar
• Simon P, Ramee MP, Boulahrouz R, et al. Epidemiologic data of primary glomerular disease in western France. Kidney Int 2004;66:905-8
   PubMed Web of Science ®Google Scholar
• Berger J, Hinglais N. Les depots intercapillaries d'IgA-IgG. J Urol Nephrol 1968;74:694-5
   PubMedGoogle Scholar
• Boyd JK, Cheung CK, Molyneux K, et al. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int 2012;81:833-43
   PubMed Web of Science ®Google Scholar
• Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int 2006;69:1939-44
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305
   PubMed Web of Science ®Google Scholar
• Conley ME, Cooper MD, Michael AF. Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest 1980;66:1432-6
   PubMed Web of Science ®Google Scholar
• Allen AC, Harper SJ, Feehally J. Galactosylation of N- and 0-linked carbohydrate moieties of IgAl and IgG in IgA nephropathy. Clin Exp Immunol 1995;100:470-4
   PubMed Web of Science ®Google Scholar
• Allen AC, Bailey EM, Brenchley PEC, et al. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int 2001;60:969-73
   PubMed Web of Science ®Google Scholar
• Hiki Y, Tanaka A, Kokubo T, et al. Analyses of IgA1 hinge glycopeptides in IgA nephropathy by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Am Soc Nephrol 1998;9:577-82
   Google Scholar
• Hiki Y, Odani H, Takahashi M, et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 2001;59:1077-85
   PubMed Web of Science ®Google Scholar
• Hiki Y, Ito A, Yamamoto Y, et al. IgA Nephropathy and aberrant glycosylation of tonsillar, serum and glomerular IgA1. Adv Otorhinolaryngol 2011;72:68-70
   Google Scholar
• Hiki Y, Kokubo T, Iwase H, et al. Underglycosylation of IgA1 hinge plays a certain role for its glomerular depostion in IgA nephropathy. J Am Soc Nephrol 1999;10:760-9
   PubMed Web of Science ®Google Scholar
• Kerr MA. The structure and function of human IgA. Biochem J 1990;271:285-96
   PubMed Web of Science ®Google Scholar
• Tarelli E, Smith AC, Hendry BM, et al. Human serum IgA1 is substituted with up to six O-glycans as shown by matrix assisted laser desorption ionisation time-of-flight mass spectrometry. Carbohydr Res 2004;339:2329-35
   PubMed Web of Science ®Google Scholar
• Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 2012;23:1579-87
   PubMed Web of Science ®Google Scholar
• Layward L, Allen AC, Hattersley JM, et al. Low antibody affinity restricted to the IgA isotype in IgA nephropathy. Clin Exp Immunol 1994;95:35-41
   Google Scholar
• Macpherson AJ, McCoy KD, Johansen FE, et al. The immune geography of IgA induction and function. Mucosal Immunol 2008;1:11-22
   PubMed Web of Science ®Google Scholar
• Buren M, Yamashita M, Suzuki Y, et al. Altered expression of lymphocyte homing chemokines in the pathogenesis of IgA nephropathy. Contrib Nephrol 2007;157:50-5
   Google Scholar
• Batra A, Smith AC, Feehally J, et al. T-cell homing receptor expression in IgA nephropathy. Nephrol Dial Transplant 2007;22:2540-8
   Google Scholar
• Kennel-De March A, Bene MC, Hurault de Ligny B, et al. Enhanced expression of CD31 and CD54 on tonsillar high endothelial venules in IgA nephropathy. Clin Immunol Immunopathol 1997;84:158-65
   PubMedGoogle Scholar
• Suzuki H, Suzuki Y, Narita I, et al. Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol 2008;19:2384-95
   PubMed Web of Science ®Google Scholar
• Park HJ, Hahn WH, Suh JS, et al. Association between Toll-like receptor 10 (TLR10) gene polymorphisms and childhood IgA nephropathy. Eur J Pediatr 2011;170:503-9
   Google Scholar
• Qin W, Zhong X, Fan JM, et al. External suppression causes the low expression of the Cosmc gene in IgA nephropathy. Nephrol Dial Transplant 2008;23:1608-14
   PubMed Web of Science ®Google Scholar
• Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 1999;104:73-81
   PubMed Web of Science ®Google Scholar
• Novak J, Vu HL, Novak L, et al. Interactions of human mesangial cells with IgA and IgA-containing immune complexes. Kidney Int 2002;62:465-75
   Google Scholar
• Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009;119:1668-77
   PubMed Web of Science ®Google Scholar
• Coppo R, Amore A, Gianoglio B, et al. Serum IgA and macromolecular IgA reacting with mesangial matrix components. Contrib Nephrol 1993;104:162-71
   Google Scholar
• Kokubo T, Hiki Y, Iwase H, et al. Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol 1998;9:2048-54
   PubMed Web of Science ®Google Scholar
• Moura IC, Centelles MN, Arcos-Fajardo M, et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 2001;194:417-25
   PubMed Web of Science ®Google Scholar
• Moura IC, Arcos-Fajardo M, Sadaka C, et al. Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol 2004;15:622-34
   PubMed Web of Science ®Google Scholar
• Moura IC, Arcos-Fajardo M, Gdoura A, et al. Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J Am Soc Nephrol 2005;16:2667-76
   Google Scholar
• Launay P, Grossetete B, Arcos-Fajardo M, et al. Fcα receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-IgA complexes in patients and CD89 transgenic mice. J Exp Med 2000;191:1999-2009
   PubMed Web of Science ®Google Scholar
• Berthelot L, Papista C, Maciel TT, et al. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J Exp Med 2012;209:793-806
   PubMed Web of Science ®Google Scholar
• Amore A, Cirina P, Conti G, et al. Glycosylation of circulating IgA in patients with IgA nephropathy modulates proliferation and apoptosis of mesangial cells. J Am Soc Nephrol 2001;12:1862-71
   Google Scholar
• Novak J, Tomana M, Matousovic K, et al. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int 2005;67:504-13
   PubMed Web of Science ®Google Scholar
• Duque N, Gómez-Guerrero C, Egido J. Interaction of IgA with Fc receptors of human mesangial cells activates transcription factor nuclear factor-B and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible PROTEIN 10. J Immunol 1997;159:3474-82
   PubMedGoogle Scholar
• Leung JCK, Tang SCW, Chan LYY, et al. Polymeric IgA increases the synthesis of macrophage migration inhibitory factor by human mesangial cells in IgA nephropathy. Nephrol Dial Transplant 2003;18:36-45
   Google Scholar
• Lai KN, Tang SCW, Guh J, et al. Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor- synthesis and signal transduction in human mesangial cells via the renin-angiotensin system. J Am Soc Nephrol 2003;14:3127-37
   PubMed Web of Science ®Google Scholar
• Leung JCK, Tang SCW, Chan LYY, et al. Synthesis of TNF- by mesangial cells cultured with polymeric anionic IgA-role of MAPK and NF-B. Nephrol Dial Transplant 2008;23:72-81
   Google Scholar
• Tam KY, Leung JCK, Chan LYY, et al. Macromolecular IgA1 taken from patients with familial IgA Nephropathy or their asymptomatic relatives have higher reactivity to mesangial cells in vitro. Kidney Int 2009;75:1330-9
   Google Scholar
• Moura I, Benhamou M, Launay P, et al. The glomerular response to IgA deposition in IgA nephropathy. Semin Nephrol 2008;28:88-95
   PubMed Web of Science ®Google Scholar
• Chan LYY, Leung JCK, Tsang AWL, et al. Activation of tubular epithelial cells by mesangial-derived TNF-a: glomerulotubular communication in IgA nephropathy. Kidney Int 2005;67:602-12
   PubMed Web of Science ®Google Scholar
• Lai KN, Leung JCK, Chan LYY, et al. Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol Dial Transplant 2009;24:62-72
   PubMed Web of Science ®Google Scholar
• Coppo R, Fonsato V, Balegno S, et al. Aberrantly glycosylated IgA1 induces mesangial cells to produce platelet-activating factor that mediates nephrin loss in cultured podocytes. Kidney Int 2010;77:417-27
   Google Scholar
• Waldherr R, Rambausek M, Duncker WD, Ritz E. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 1989;4:943-6
   PubMed Web of Science ®Google Scholar
• Suzuki K, Honda K, Tanabe K, et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003;63:2286-94
   PubMed Web of Science ®Google Scholar
• Reich HN, Troyanov S, Scholey JW, Cattran DC. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007;18:3177-83
   PubMed Web of Science ®Google Scholar
• D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 24:179-96.2004
   PubMed Web of Science ®Google Scholar
• Berthoux F, Mohey H, Laurent B, et al. Predicting the risk of dialysis or death in IgA nephropathy. J Am Soc Nephrol 2011;22:752-61
   PubMed Web of Science ®Google Scholar
• Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol 2005;18:503-12
   PubMed Web of Science ®Google Scholar
• Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001;110:434-7
   PubMed Web of Science ®Google Scholar
• Shen P, He L, Huang D. Clinical course and prognostic factors of clinical early IgA nephropathy. Neth J Med 2008;66:242-7
   PubMed Web of Science ®Google Scholar
• Gutierrrez E, Zamora I, Ballarin JA, et al. (GLOSEN). Long-term outcome of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol 2012;23:1753-60
   Google Scholar
• Moroni G, Longhi S, Quaglini S, et al. The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. Nephrol Dial Transplant 2013;28:1305-14
   Google Scholar
• Floege J, Gröne HJ. Recurrent IgA-nephropathy in the renal allograft: not a benign condition. Nephrol. Dial. Transplant 2013;28:1070-3
   PubMed Web of Science ®Google Scholar
• Flöge J, Eitner F. Current therapy for IgA nephropathy. J Am Soc Nephrol 2011;22:1785-94
   Google Scholar
• Floege J, Feehally J. Treatment of IgA nephropathy and Henoch–Schönlein nephritis. Nat Rev Nephrol 2013;9:320-7
   PubMed Web of Science ®Google Scholar
• A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009;76:534-45
   Google Scholar
• Goto M, Wakai K, Kawamura T, et al. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant 2009;24:3068-74
   PubMed Web of Science ®Google Scholar
• Xie J, Kiryluk K, Wang W, et al. Predicting Progression of IgA Nephropathy: new Clinical Progression Risk Score. PLoS One 2012;7:e38904
   PubMed Web of Science ®Google Scholar
• Zhao N, Hou P, Lv J, et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 2012;82:790-6
   PubMed Web of Science ®Google Scholar
• Xu L, Zhao M. Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy. Kidney Int 2005;68:167-72
   PubMed Web of Science ®Google Scholar
• Camilla R, Suzuki H, Dapra V, et al. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol 2011;6:1903-11
   PubMed Web of Science ®Google Scholar
• Moldoveanu Z, Wyatt RJ, Lee JY, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 2007;71:1148-54
   PubMed Web of Science ®Google Scholar
• KDIGO Work Group. Chapter 10: immunoglobulin A nephropathy. Kidney Int Supp 2012;2:209-17
   Google Scholar
• Praga M, Gutierrez E, Gonzalez E, et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003;14:1578-83
   PubMed Web of Science ®Google Scholar
• Li PK, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006;47:751-60
   PubMed Web of Science ®Google Scholar
• Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53
   PubMed Web of Science ®Google Scholar
• Tang SC, Lin M, Tam S, et al. Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study. Nephrol Dial Transplant 2012;27:613-18
   PubMed Web of Science ®Google Scholar
• Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: A randomized controlled trial. Lancet 1999;353:883-7
   PubMed Web of Science ®Google Scholar
• Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004;15:157-63
   PubMed Web of Science ®Google Scholar
• Manno C, Torres DD, Rossini M, et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009;24:3694-701
   PubMed Web of Science ®Google Scholar
• Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 2009;53:26-32
   PubMed Web of Science ®Google Scholar
• Eitner F, Ackermann D, Hilgers RFloege J. Supportive versus immunosuppressive Therapy of Progressive igA nephropathy (sTOP) igAn trial: rationale and study protocol. J Nephrol 2008;21:284-9
   Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online]. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01560052?term=testing&rank=9
   Google Scholar
• Smerud H, Barany P, Lindström K, et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant 2011;26:3237-42
   PubMed Web of Science ®Google Scholar
• Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004;65:1842-9
   PubMed Web of Science ®Google Scholar
• Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005;20:2139-45
   PubMed Web of Science ®Google Scholar
• Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005;68:802-12
   PubMed Web of Science ®Google Scholar
• Tang SC, Tang AW, Wong SS, et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 2010;77:543-9
   PubMed Web of Science ®Google Scholar
• Lv J, Zhang H, Cui Z, et al. Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. Nephrol Dial Transplant 2008;23:2868-72
   PubMed Web of Science ®Google Scholar
• Pozzi C, Andrulli S, Pani A, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 2010;21:1783-90
   PubMedGoogle Scholar
• Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002;13:142-8
   PubMed Web of Science ®Google Scholar
• Cruzado JM, Poveda R, Ibernon M, et al. Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy. Nephrol Dial Transplant 2011;26:3596-602
   Google Scholar
• Krebs S, Omer B, Omer TN, et al. Wormwood (Artemisia absinthium) for poorly responsive early-stage IgA nephropathy: a pilot uncontrolled trial. Am J Kidney Dis 2010;56:1095-9
   Google Scholar
• Donadio Jr JV, Grande JP, Bergstralh EJ, et al. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol 1999;10:1772-7
   Google Scholar
• Hogg RJ, Lee J, Nardelli N, et al. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006;1:467-74
   Google Scholar
• Strippoli GF, Manno C, Schena FP. An ‘evidence-based' survey of therapeutic options for IgA nephropathy: assessment and criticism. Am J Kidney Dis 2003;41:1129-39
   PubMedGoogle Scholar
• Xie Y, Nishi S, Ueno M, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 2003;63:1861-7
   PubMed Web of Science ®Google Scholar
• Komatsu H, Fujimoto S, Hara S, et al. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol 2008;3:1301-7
   Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (RIT) anti-CD20 monoclonal antibody therapy in patients treated with relapsed low grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95
   PubMed Web of Science ®Google Scholar
• Sugiura H, Takei T, Itabashi M, et al. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract 2011;117:c98-105
   PubMed Web of Science ®Google Scholar
• Gaballa MR, Laubach JP, Schlossman RL, et al. Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev. Hematology 2012;5:51-68
   Google Scholar
• Gómez-Guerrero C, Duque N, Egido J. Stimulation of Fc(alpha) receptors induces tyrosine phosphorylation of phospholipase C-gamma(1), phosphatidylinositol phosphate hydrolysis, and Ca2+ mobilization in rat and human mesangial cells. J Immunol 1996;156:4369-76
   Google Scholar
• Kim MJ, McDaid JP, McAdoo SP, et al. Spleen Tyrosine Kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients. J Immunol 2012;189:3751-8
   PubMed Web of Science ®Google Scholar
• Cattran DC, Coppo R, Cook HT, et al. The Oxford Classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009;76:534-45
   PubMed Web of Science ®Google Scholar
• Stangou M, Alexopoulos E, Papagianni A, et al. Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy. Nephrology 2009;14:613-20
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Wada T, Furuichi K, et al. Urinary levels of chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy. J Leukoc Biol 1998;63:493-9
   PubMed Web of Science ®Google Scholar
• Available from: http://www.orpha.net
   Google Scholar